ChIP‐Seq of ERα and RNA polymerase II defines genes differentially responding to ligands

We used ChIP‐Seq to map ERα‐binding sites and to profile changes in RNA polymerase II (RNAPII) occupancy in MCF‐7 cells in response to estradiol (E2), tamoxifen or fulvestrant. We identify 10 205 high confidence ERα‐binding sites in response to E2 of which 68% contain an estrogen response element (ERE) and only 7% contain a FOXA1 motif. Remarkably, 596 genes change significantly in RNAPII occupancy (59% up and 41% down) already after 1 h of E2 exposure. Although promoter proximal enrichment of RNAPII (PPEP) occurs frequently in MCF‐7 cells (17%), it is only observed on a minority of E2‐regulated genes (4%). Tamoxifen and fulvestrant partially reduce ERα DNA binding and prevent RNAPII loading on the promoter and coding body on E2‐upregulated genes. Both ligands act differently on E2‐downregulated genes: tamoxifen acts as an agonist thus downregulating these genes, whereas fulvestrant antagonizes E2‐induced repression and often increases RNAPII occupancy. Furthermore, our data identify genes preferentially regulated by tamoxifen but not by E2 or fulvestrant. Thus (partial) antagonist loaded ERα acts mechanistically different on E2‐activated and E2‐repressed genes.

[1]  M. Rechler Insulin-like growth factor binding proteins. , 1993, Vitamins and hormones.

[2]  S. Adler,et al.  Differential positive and negative transcriptional regulation by tamoxifen. , 1995, Endocrinology.

[3]  J. Pink,et al.  Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. , 1996, Cancer research.

[4]  L. Leung,et al.  Regulation of death promoter Bak expression by cell density and 17 beta-estradiol in MCF-7 cells. , 1998, Cancer letters.

[5]  Myles Brown,et al.  Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription , 2000, Cell.

[6]  M. Macleod,et al.  Effects of estrogen on global gene expression: identification of novel targets of estrogen action. , 2000, Cancer research.

[7]  A. Fabiato,et al.  Anonymity of reviewers , 1994 .

[8]  Simak Ali,et al.  Endocrine-responsive breast cancer and strategies for combating resistance , 2002, Nature Reviews Cancer.

[9]  P. V. van Diest,et al.  Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment , 2002, British Journal of Cancer.

[10]  H. Hurst,et al.  Targeting of SWI/SNF chromatin remodelling complexes to estrogen‐responsive genes , 2002, The EMBO journal.

[11]  Jun S. Liu,et al.  An algorithm for finding protein–DNA binding sites with applications to chromatin-immunoprecipitation microarray experiments , 2002, Nature Biotechnology.

[12]  Alexander E. Kel,et al.  TRANSFAC®: transcriptional regulation, from patterns to profiles , 2003, Nucleic Acids Res..

[13]  Barry Komm,et al.  Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. , 2003, Endocrinology.

[14]  K. Coser,et al.  Global analysis of ligand sensitivity of estrogen inducible and suppressible genes in MCF7/BUS breast cancer cells by DNA microarray , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  K. Coser,et al.  The Bik BH3-only protein is induced in estrogen-starved and antiestrogen-exposed breast cancer cells and provokes apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Marc E. Lippman,et al.  GREB1 is a critical regulator of hormone dependent breast cancer growth , 2005, Breast Cancer Research and Treatment.

[17]  W. Lam,et al.  Comprehensive copy number profiles of breast cancer cell model genomes , 2006, Breast Cancer Research.

[18]  Clifford A. Meyer,et al.  Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 , 2005, Cell.

[19]  Leah Barrera,et al.  A high-resolution map of active promoters in the human genome , 2005, Nature.

[20]  S. Andò,et al.  Endogenous Coactivator ARA70 Interacts with Estrogen Receptor α (ERα) and Modulates the Functional ERα/Androgen Receptor Interplay in MCF-7 Cells* , 2005, Journal of Biological Chemistry.

[21]  Clifford A. Meyer,et al.  Genome-wide analysis of estrogen receptor binding sites , 2006, Nature Genetics.

[22]  J. Bartlett,et al.  Bad expression predicts outcome in patients treated with tamoxifen , 2007, Breast Cancer Research and Treatment.

[23]  H. Phatnani,et al.  Phosphorylation and functions of the RNA polymerase II CTD. , 2006, Genes & development.

[24]  Chin-Yo Lin,et al.  Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. , 2006, Cancer research.

[25]  Anthony Howell,et al.  Pure oestrogen antagonists for the treatment of advanced breast cancer. , 2006, Endocrine-related cancer.

[26]  Mark Bieda,et al.  Unbiased location analysis of E2F1-binding sites suggests a widespread role for E2F1 in the human genome. , 2006, Genome research.

[27]  F. Stossi,et al.  Estrogen-occupied Estrogen Receptor Represses Cyclin G2 Gene Expression and Recruits a Repressor Complex at the Cyclin G2 Promoter* , 2006, Journal of Biological Chemistry.

[28]  H. Stunnenberg,et al.  Identification of novel functional TBP‐binding sites and general factor repertoires , 2007, The EMBO journal.

[29]  S. Baek,et al.  Breast Cancer Cell Proliferation Is Inhibited by BAD , 2007, Journal of Biological Chemistry.

[30]  Manolis Kellis,et al.  RNA polymerase stalling at developmental control genes in the Drosophila melanogaster embryo , 2007, Nature Genetics.

[31]  Ruchir Shah,et al.  RNA polymerase is poised for activation across the genome , 2007, Nature Genetics.

[32]  Y. Kluger,et al.  Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer , 2008, Breast Cancer Research.

[33]  Andrew G. Clark,et al.  Genomic Analyses of Transcription Factor Binding, Histone Acetylation, and Gene Expression Reveal Mechanistically Distinct Classes of Estrogen-Regulated Promoters , 2007, Molecular and Cellular Biology.

[34]  Barry Komm,et al.  Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation. , 2007, Molecular endocrinology.

[35]  R. Young,et al.  A Chromatin Landmark and Transcription Initiation at Most Promoters in Human Cells , 2007, Cell.

[36]  Marina Bibikova,et al.  Sensitive ChIP-DSL technology reveals an extensive estrogen receptor α-binding program on human gene promoters , 2007, Proceedings of the National Academy of Sciences.

[37]  Dirk Eick,et al.  Transcribing RNA Polymerase II Is Phosphorylated at CTD Residue Serine-7 , 2007, Science.

[38]  F. Stossi,et al.  Whole-Genome Cartography of Estrogen Receptor α Binding Sites , 2007, PLoS genetics.

[39]  John F Smyth,et al.  Insulin-like Growth Factor Binding Proteins IGFBP3, IGFBP4, and IGFBP5 Predict Endocrine Responsiveness in Patients with Ovarian Cancer , 2007, Clinical Cancer Research.

[40]  John H. White,et al.  Regulation of GREB1 Transcription by Estrogen Receptor α through a Multipartite Enhancer Spread Over 20 kb of Upstream Flanking Sequences* , 2007, Journal of Biological Chemistry.

[41]  D. Cameron,et al.  Insulin-like Growth Factor Binding Proteins IGFBP 3 , IGFBP 4 , and IGFBP 5 Predict Endocrine Responsiveness in Patients with Ovarian Cancer , 2007 .

[42]  Steven J. M. Jones,et al.  FindPeaks 3.1: a tool for identifying areas of enrichment from massively parallel short-read sequencing technology , 2008, Bioinform..

[43]  Hans Clevers,et al.  Genome-Wide Pattern of TCF7L2/TCF4 Chromatin Occupancy in Colorectal Cancer Cells , 2008, Molecular and Cellular Biology.

[44]  J. Stamatoyannopoulos,et al.  Interaction of the Glucocorticoid Receptor with the Chromatin Landscape , 2008, Molecular cell.

[45]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[46]  Leighton J. Core,et al.  Nascent RNA Sequencing Reveals Widespread Pausing and Divergent Initiation at Human Promoters , 2008, Science.

[47]  Leighton J. Core,et al.  Postrecruitment Regulation of RNA Polymerase II Directs Rapid Signaling Responses at the Promoters of Estrogen Target Genes , 2008, Molecular and Cellular Biology.

[48]  R. Weiss,et al.  Loss of Hus1 sensitizes cells to etoposide-induced apoptosis by regulating BH3-only proteins , 2008, Oncogene.

[49]  Clifford A. Meyer,et al.  FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription , 2008, Cell.

[50]  J. Lis,et al.  Rapid, Transcription-Independent Loss of Nucleosomes over a Large Chromatin Domain at Hsp70 Loci , 2008, Cell.

[51]  E. Avvedimento,et al.  DNA Oxidation as Triggered by H3K9me2 Demethylation Drives Estrogen-Induced Gene Expression , 2008, Science.

[52]  H. Stunnenberg,et al.  Characterization of genome-wide p53-binding sites upon stress response , 2008, Nucleic acids research.

[53]  D. Germain,et al.  Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. , 2008, Cancer research.